# Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

> **NCT00820755** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 583 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Cetuximab plus Platinum-based Doublet Chemotherapy
- **DRUG:** Cetuximab 500 mg/m^2
- **DRUG:** Cetuximab 250 mg/m^2

## Key facts

- **NCT ID:** NCT00820755
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-12
- **Final completion:** 2013-06
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820755, "Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00820755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*